Comprehensive Approach to Sarcopenia Treatment
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Sarcopenia is characterized by progressive and generalized loss of skeletal muscle mass and strength with a risk of adverse outcomes such as physical disability, poor quality of life, and death. Primary sarcopenia is considered to be age-related when no other cause is evident, other than ageing itself. Secondary sarcopenia should be considered when one or more other causes are evident, such as activity-, disease-, or nutrition-related sarcopenia. In this narrative review that focused on human studies, we summarize the pharmaceutical therapies (testosterone, dehydroepiandrosterone, estrogen, growth hormone, ghrelin, vitamin D, angiotensin converting enzyme inhibitor, and eicosapentaenoic acid) and nonpharmaceutical therapies (resistance training, protein and amino acid supplementation, and non-smoking) for counteracting primary sarcopenia. Testosterone and growth hormone improve muscle mass and muscle strength, but have several side effects. Although there are some intriguing pharmaceutical therapies to combat sarcopenia, resistance training combined with supplements containing amino acids are the most effective for preventing and treating age-related muscle wasting and weakness. The etiology of sarcopenia in the elderly is multi-factorial. Patients with disuse syndrome and deconditioning often complicate the diagnosis, of not only activity-related sarcopenia, but also age-, disease-, and nutrition-related sarcopenia. In these cases a comprehensive approach to sarcopenia treatment should include pharmaceutical therapies for age-related sarcopenia and comorbid chronic diseases, resistance training, early ambulation, nutrition management, protein and amino acid supplementation, and non-smoking. The effect of pharmaceutical therapies for sarcopenia can be enhanced by this comprehensive approach. Future research on pharmaceutical therapies for counteracting sarcopenia should consider non-pharmaceutical therapies and also the causes of sarcopenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology of Sarcopenia among the Elderly in New Mexico
Baumgartner, R. N., Koehler, K. M., Gallagher, D., Romero, L., Heymsfield, S. B., Ross, R. R., Garry, P. J., & Lindeman, R. D. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009520 · Cited by 4,004
Fielding, R. A., Vellas, B., Evans, W. J., Bhasin, S., Morley, J. E., Newman, A. B., Abellan van Kan, G., Andrieu, S., Bauer, J., Breuille, D., et al. (2011) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2011.01.003 · Cited by 3,256
Sarcopenia: origins and clinical relevance
Rosenberg, I. H. (1997) · The Journal of Nutrition · doi:10.1093/jn/127.5.990s · Cited by 2,399
Houston, D. K., Nicklas, B. J., Ding, J., Harris, T. B., Tylavsky, F. A., Newman, A. B., Lee, J. S., Sahyoun, N. R., Visser, M., & Kritchevsky, S. B. (2008) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/87.1.150 · Cited by 1,214
Weight loss, exercise, or both and physical function in obese older adults
Villareal, D. T., Chode, S., Parimi, N., Sinacore, D. R., Hilton, T., Armamento-Villareal, R., Napoli, N., Qualls, C., & Shah, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008234 · Cited by 1,096
Sarcopenia as a risk factor for falls in elderly individuals: results from the ilSIRENTE study
Landi, F., Liperoti, R., Russo, A., Giovannini, S., Tosato, M., Capoluongo, E., Bernabei, R., & Onder, G. (2012) · Clinical Nutrition · doi:10.1016/j.clnu.2012.02.007 · Cited by 938
Cermak, N. M., Res, P. T., de Groot, L. C., Saris, W. H., & van Loon, L. J. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.112.037556 · Cited by 827
Adverse Effects of Testosterone Therapy in Adult Men: A Systematic Review and Meta-Analysis
Fernández-Balsells, M. M., Murad, M. H., Lane, M., Lampropulos, J. F., Albuquerque, F., Mullan, R. J., Agrwal, N., Elamin, M. B., Gallegos-Orozco, J. F., Wang, A. T., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2575 · Cited by 713
Smith, G. I., Atherton, P., Reeds, D. N., Mohammed, B. S., Rankin, D., Rennie, M. J., & Mittendorfer, B. (2011) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.110.005611 · Cited by 665
Kim, H. K., Suzuki, T., Saito, K., Yoshida, H., Kobayashi, H., Kato, H., & Katayama, M. (2012) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2011.03776.x · Cited by 551
Cited by
Pathogenesis and Management of Sarcopenia
Dhillon, R. J. S., & Hasni, S. (2017) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2016.08.002 · Cited by 574
“These agents have a modest positive effect on muscle strength and mass but are of limited use due to adverse effects, such as increased risk of prostate cancer in men, virilization in women, and an overall increased risk of cardiovascular events.(30,31) New therapies for sarcopenia are in clinical development.”
BackgroundRondanelli, M., Klersy, C., Terracol, G., Talluri, J., Maugeri, R., Guido, D., Faliva, M. A., Solerte, B. S., Fioravanti, M., Lukaski, H., et al. (2016) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.115.113357 · Cited by 412
Yoshimura, Y., Wakabayashi, H., Yamada, M., Kim, H., Harada, A., & Arai, H. (2017) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2017.03.019 · Cited by 365
Self-citationWakabayashi, H., & Sakuma, K. (2014) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-014-0162-x · Cited by 334
Self-citationCachexia and sarcopenia: mechanisms and potential targets for intervention
Argilés, J. M., Busquets, S., Stemmler, B., & López-Soriano, F. J. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.04.003 · Cited by 324
Metadata
- Authors
- Wakabayashi, H., & Sakuma, K.
- Venue
- Current Clinical Pharmacology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2014-04
- Volume
- 9
- Issue
- 2
- Pages
- 171-180
- ISSN
- 1574-8847 (ISSN-L)
- OpenAlex
- W2324831040
- Cited by
- 69
- References
- 24
- FWCI
- 4.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comprehensive Approach to Sarcopenia Treatment. https://app.cochat.ai/papers/10.2174/1574884708666131111192845
- The paper
- Wakabayashi, H., & Sakuma, K. (2014). Comprehensive Approach to Sarcopenia Treatment. Current Clinical Pharmacology. https://doi.org/10.2174/1574884708666131111192845
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.